Congested OTC Monograph Process Can Leave Manufacturers Confused
This article was originally published in The Tan Sheet
Executive Summary
The disparity between FDA's OTC monographs and up-to-date communications from the agency can create confusion for manufacturers, Office of New Drugs Director John Jenkins acknowledges
You may also be interested in...
Sea Changes In Regulation And The Market: Top Stories Of 2008
When an iconic drug brand drew scrutiny on Capitol Hill for possibly violating FDA's policy against combinations of drugs and dietary supplements, OTC and supplement interests took notice
FDA Working Group Considering Changes To OTC Cough/Cold Monograph
An FDA working group conducting a review of OTC cough and cold medicines for 2- to 11-year-old children will make recommendations this spring on actions the agency should take concerning use of the products for that age group, Office of Nonprescription Products officials said Jan. 17
Data Support Phenylephrine Efficacy, But More Studies Needed – NDAC
FDA's Nonprescription Drugs Advisory Committee recommends additional studies on phenylephrine efficacy for treatment of nasal congestion, although members say current data support the efficacy of the OTC cough/cold ingredient